Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment regimen change Clear all
Recruiting Not applicable Interventional

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

NCT05958316
View directory record Official record
Conditions
Symptoms and Signs, Cancer, Childhood Cancer
Interventions
Computerized Symptom Capture Tool (C-SCAT) Intervention, Usual Care Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 29 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Kansas City, Missouri • Salt Lake City, Utah • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

Sit Less, Interact and Move More (SLIMM) 2 Study

NCT05173714
View directory record Official record
Conditions
Chronic Kidney Diseases, Obesity
Interventions
SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
Behavioral · Drug
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
20 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Results available

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy

NCT01817374
View directory record Official record
Conditions
Breast Cancer
Interventions
2D US grayscale plus quantitative VCEUS
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

NCT00888108
View directory record Official record
Conditions
Solid Tumor
Interventions
ABT-263, Docetaxel
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Fort Lauderdale, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage

NCT03302559
View directory record Official record
Conditions
Skin Care
Interventions
Retinol Complex 0.5, Facial cleanser, Moisturizing lotion, Sunscreen, Skin Imaging
Other · Device
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HELP-HY: Health Education and sLeep Program in HYpertension

NCT03255746
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Sleep Enhancement, Health Education
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)

NCT00974259
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Management protocol based on pBrO2 and ICP values., Management protocol based on ICP values only.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Miami, Florida • Durham, North Carolina • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 2, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Results available

Management of Uncontrolled Hypertension (HTN)

NCT02922023
View directory record Official record
Conditions
Hypertension
Interventions
Ambulatory blood pressure monitor (ABPM), Chronotherapy
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

NCT00587444
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Heparin, HH or high heparin, heparin concentration HC
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT04469556
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer
Interventions
Folfirinox, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee

NCT05318521
View directory record Official record
Conditions
Degenerative Arthritis
Interventions
Placebo, Ibuprofen modified release tablet 800 mg
Drug
Lead sponsor
Overseas Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • Santa Ana, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Results available

ORCA - Oracea® for Rosacea: A Community-based Assessment

NCT00892281
View directory record Official record
Conditions
Rosacea
Interventions
doxycycline (Oracea®) 40 mg modified release as monotherapy, doxycycline (Oracea®) 40 mg modified release as add-on therapy
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
1,421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330
View directory record Official record
Conditions
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions
Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
154
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

NCT03339401
View directory record Official record
Conditions
Adenovirus
Interventions
Standard of Care, Brincidofovir
Other · Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

NCT00282256
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus modified release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Up to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 2, 2026, 5:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

NCT03352765
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 1 Interventional

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 2, 2026, 5:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

NCT07591649
View directory record Official record
Conditions
Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Interventions
AdaptNK, Fludarabine, Cyclophosphamide, IL-2
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 2, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Kick Out Parkinson's Disease 2

NCT03882879
View directory record Official record
Conditions
Parkinson Disease
Interventions
Karate Classes, Pre-Intervention Study Visit, Bimonthly Online Survey, 6-month Study Visit, 12-month Study Visit
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 2, 2026, 5:23 AM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

NCT03488225
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 5:23 AM EDT